EPA/DHA Omega-3 Market Size, Share, Growth, and Industry Analysis, By Type (Capsule EPA, Powder EPA), By Application (Infant Formula, Fortified Foods and Beverages, Nutritional Supplements, Pharmaceuticals, Clinical Nutrition), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

EPA/DHA OMEGA-3 MARKET OVERVIEW

The global EPA/DHA Omega-3 Market is valued at USD 94.43 Billion in 2026 and is projected to reach USD 222.43 Billion by 2035. It grows at a compound annual growth rate (CAGR) of around 10% from 2026 to 2035.

The EPA/DHA omega-3 market covers eicosapentaenoic acid and docosahexaenoic acid ingredients sourced from fish oil, krill, and microalgae, delivered through capsules, powders, emulsions, and fortified formulations. These long-chain fatty acids support cardiovascular, cognitive, visual, and prenatal health, which keeps demand steady across supplements, pharmaceuticals, and infant nutrition. Global EPA/DHA omega-3 consumption reached 132,000 metric tons in 2025, and concentrated oils above 60% purity now represent 47.3% of ingredient volume. Buyers increasingly favor third-party tested, triglyceride-form products with low oxidation values, pushing manufacturers toward molecular distillation, enzymatic re-esterification, and traceable sourcing from certified fisheries and algal fermentation facilities.

The United States remains the most mature consumer base for EPA/DHA omega-3 products, supported by strong physician awareness, wide retail distribution, and an established dietary supplement framework. American shoppers actively compare labels for EPA and DHA content per serving, purity certifications, and fish-source transparency, which rewards brands that publish independent test results. Prescription omega-3 therapies for triglyceride management add clinical credibility, while e-commerce platforms have helped direct-to-consumer brands compete with legacy names. Demand is also rising for prenatal formulas, sports nutrition, and pet supplements, and regulatory guidance on structure-function claims continues to shape product positioning and marketing language across the country.

KEY FINDINGS

LATEST TRENDS

The EPA/DHA omega-3 market is shifting toward higher concentration, cleaner sourcing, and more convenient formats. Re-esterified triglyceride forms are gaining favor over ethyl esters because of perceived absorption benefits and premium positioning. Algal-derived EPA/DHA accounted for 14.2% of new product launches in 2025, reflecting growing vegan demand and concern over marine resource pressure. Sustainability claims, including certified fisheries and carbon footprint labeling, have become important purchase factors in Europe and North America.

Personalized nutrition is another major trend, with omega-3 index testing kits helping consumers track blood levels and adjust dosage. Gummies, liquid emulsions, and flavored sachets are attracting children, older adults, and people who struggle with large softgels. Brands are also targeting specific life stages and conditions, including prenatal care, cognitive aging, sports recovery, eye health, and mood support. Digital commerce continues to reshape competition, as direct-to-consumer brands use subscription models and published purity test results to build trust. Pet omega-3 supplements are also expanding as owners seek joint and coat health solutions.

•   
•   
  

  Download Free Sample to learn more about this report

    

EPA/DHA OMEGA-3 MARKET SEGMENTATION

By Type

• Capsule EPA: Capsule EPA holds a 68.4% share of the EPA/DHA omega-3 market, making it the dominant delivery format worldwide. Softgels and enteric-coated capsules provide precise dosing, convenient daily use, and protection against oxidation and fishy aftertaste. Most high-concentration products, including triglyceride and ethyl ester concentrates above 60% purity, are sold in capsule form, which supports premium positioning. Pharmacies, supermarkets, and online stores stock wide capsule assortments for heart, brain, joint, and prenatal health. Plant-based capsule shells made from carrageenan and modified starch are also expanding the segment among vegetarian and halal-conscious consumers, while blister packaging and nitrogen-flushed bottles help maintain freshness during distribution.

• Powder EPA: Powder EPA accounts for a 31.6% share and is gaining traction as food, beverage, and infant formula producers seek stable omega-3 ingredients that blend easily into dry mixes. Microencapsulation and spray-drying technologies coat EPA/DHA oil droplets with proteins, starches, or gums, improving oxidative stability and masking fish taste. Powders are widely used in fortified dairy, bakery products, nutrition bars, sachets, and medical nutrition blends. Manufacturers value longer shelf life and simpler handling compared with liquid oils. Rising demand for gummies, effervescent drinks, and ready-to-mix sports nutrition formats further supports powder EPA adoption, especially in Asia Pacific and Europe where fortified foods are expanding quickly.

By Application

• Infant Formula: Infant formula represents a 16.3% share of the EPA/DHA omega-3 market, supported by the essential role of DHA in brain and retina development during early life. Regulations in the European Union require DHA addition to infant and follow-on formula, which has made this ingredient a standard component rather than an optional premium feature. Algal DHA dominates this application because it offers consistent purity, low contaminant levels, and reliable supply. Formula makers also pair DHA with arachidonic acid to mirror the fatty acid profile of breast milk. Growing birth rates in parts of South Asia and Africa, along with premium formula demand in China, sustain steady consumption.

• Fortified Foods and Beverages: Fortified foods and beverages hold a 13.5% share, driven by consumers who prefer receiving omega-3 through daily diets rather than pills. EPA/DHA is added to milk, yogurt, juices, eggs, bread, spreads, and plant-based beverages, often in microencapsulated powder or emulsion form. Food makers face technical hurdles such as heat stability, flavor masking, and shelf life, yet improved encapsulation has made fortification more practical. Health claims linked to heart and brain function attract health-conscious families and older adults. 

• Nutritional Supplements: Nutritional supplements lead with a 41.2% share, making them the largest application in the EPA/DHA omega-3 market. Fish oil, krill oil, and algal oil supplements are among the most widely used dietary supplements globally, purchased for heart, brain, joint, eye, and prenatal health. Consumers increasingly select triple-strength and high-concentration formats that deliver more EPA and DHA in fewer capsules. Direct-to-consumer brands use transparency, independent purity testing, and subscription models to build loyalty. Pharmacist and physician recommendations reinforce purchase decisions, and sports nutrition users are adding omega-3 for recovery and inflammation support, steadily widening the supplement customer base across age groups.

• Pharmaceuticals: Pharmaceuticals account for a 19.6% share, built on prescription omega-3 drugs used to manage severe hypertriglyceridemia and reduce cardiovascular risk. Icosapent ethyl, a highly purified EPA ethyl ester, has been approved in Japan since 1990 and gained wider use after major cardiovascular outcome trials. Prescription formulations require pharmaceutical-grade purity, often above 90% concentration, and strict good manufacturing practice standards. Generic entries have improved affordability and expanded patient access in North America and Europe. 

• Clinical Nutrition: Clinical nutrition holds a 9.4% share and includes enteral feeds, oral nutritional supplements, and parenteral lipid emulsions used in hospitals and long-term care. EPA and DHA support patients facing cancer-related weight loss, surgical recovery, critical illness, and chronic inflammation. Fish oil-based lipid emulsions are widely used in intensive care and for preterm infants requiring intravenous nutrition. Hospitals value products with consistent dosing and proven tolerability, and dietitians increasingly include omega-3 in protocols for elderly and malnourished patients. Aging populations, rising chronic disease rates, and expanding home healthcare services in Europe and North America continue to support steady clinical nutrition demand.

MARKET DYNAMICS

Driving Factor

Rising prevalence of cardiovascular disease and preventive health awareness

Cardiovascular disease remains the leading cause of death worldwide, accounting for 17.9 million deaths each year, and this burden keeps EPA and DHA at the center of preventive nutrition. Physicians, dietitians, and pharmacists increasingly recommend omega-3 intake for triglyceride management, blood pressure support, and inflammation control, which strengthens repeat purchasing. Consumers are also linking DHA with brain development, eye health, and healthy aging, broadening the buyer base beyond heart patients. Aging populations in North America, Europe, and East Asia add steady volume, while younger consumers adopt omega-3 products through sports nutrition and cognitive wellness routines. Clinical research on prescription EPA has further raised confidence in high-purity concentrates across retail and clinical channels.

Driver Impact Analysis*

Restraining Factor

Volatile raw material supply and fishery dependence

The EPA/DHA omega-3 market depends heavily on small pelagic fish such as anchovy, sardine, and menhaden, making supply vulnerable to climate patterns and fishing quotas. Peru cancelled its first anchovy fishing season in 2023 due to El Niño conditions, tightening crude fish oil availability and squeezing margins for refiners and finished product brands. Such disruptions raise input costs, delay production schedules, and force formulators to reformulate or accept lower concentration grades. Sustainability concerns about forage fish harvesting also influence retailer sourcing policies and consumer perception. Smaller brands without long-term supply contracts face the greatest exposure, and price spikes can push cost-sensitive buyers toward lower-dose or alternative supplements.

Restraint Impact Analysis*

Expansion of algal and fermentation-based omega-3 sources

Opportunity

Microalgae and fermentation-based EPA/DHA offer a scalable route around marine supply limits and open access to vegan, vegetarian, and allergy-conscious consumers. Algal oils already dominate DHA supply for infant formula, and production technology now supports higher EPA yields suitable for adult supplements.

Algal-derived EPA/DHA accounted for 14.2% of new product launches in 2025, showing strong commercial momentum. These ingredients carry low contaminant risk, consistent quality, and clear traceability, which suits pharmaceutical and clinical nutrition buyers. Brands that combine algal sourcing with clean-label positioning, plant-based softgels, and carbon footprint disclosures can command premium shelf space and attract new demographic groups that previously avoided fish-derived products.

Oxidation control and product quality consistency

Challenge

EPA and DHA are highly polyunsaturated, which makes them prone to oxidation during refining, encapsulation, storage, and transport. Oxidized oils produce fishy odor, aftertaste, and reflux, and they may reduce consumer trust when independent tests reveal peroxide or anisidine values above recommended limits.

Maintaining low oxidation requires nitrogen flushing, antioxidant blends, cold chain handling, and specialized packaging, all of which add cost. Label accuracy is another concern, as some products deliver less EPA and DHA than claimed. Manufacturers must invest in batch testing, certificates of analysis, and third-party certification to protect brand reputation, while regulators continue to scrutinize claims, contaminant thresholds, and labeling practices.

• Download Free Sample to learn more about this report

•  

EPA/DHA OMEGA-3 MARKET REGIONAL INSIGHTS

• North America

North America holds a 36.8% share of the EPA/DHA omega-3 market, making it the largest regional market. The United States contributes 84.6% of regional consumption, supported by high supplement usage, broad pharmacy networks, and strong physician recommendations for heart health. Canada accounts for 12.1% of regional demand, where natural health product licensing builds consumer confidence in label claims. The region has a large base of prescription omega-3 users for triglyceride management, and generic EPA products have widened patient access. Direct-to-consumer brands, warehouse clubs, and online marketplaces drive high-concentration capsule sales. Consumers show a strong preference for third-party tested, triglyceride-form products and transparent fish sourcing. 

• Europe

Europe holds a 27.5% share of the EPA/DHA omega-3 market, supported by strong regulatory frameworks and long-standing fish oil consumption traditions. Germany, France, and the United Kingdom together account for 52.3% of regional demand, driven by pharmacy-led supplement sales and fortified foods. The European Food Safety Authority recommends 250 mg of EPA and DHA daily for adults, a benchmark that shapes product dosing and marketing. Norway serves as a major hub for omega-3 refining, concentration, and krill processing, supplying ingredients across the continent and beyond. Mandatory DHA inclusion in infant formula sustains steady ingredient demand. Consumers in Nordic and Western European countries prioritize sustainability certifications and low environmental impact sourcing. 

• Asia Pacific

Asia Pacific holds a 24.7% share and remains the fastest-growing region in the EPA/DHA omega-3 market. China accounts for 38.6% of regional consumption, driven by premium infant formula, cross-border e-commerce, and rising middle-class health spending. Japan has one of the longest histories of prescription EPA use, and its high fish intake culture supports strong acceptance of omega-3 functional foods. Australia and New Zealand serve as important supplement manufacturing and export hubs with strict therapeutic goods regulations that strengthen quality perception. India and Southeast Asian countries are emerging markets where urban consumers increasingly purchase omega-3 capsules through online pharmacies. 

• Middle East & Africa

Middle East & Africa holds a 6.2% share of the EPA/DHA omega-3 market, with growth concentrated in Gulf Cooperation Council countries and South Africa. Saudi Arabia and the United Arab Emirates together account for 44.7% of regional demand, supported by high disposable incomes, expanding pharmacy chains, and government wellness programs. Low fish consumption in many inland areas creates a nutritional gap that supplements and fortified foods can address. Halal certification is a key purchase factor, encouraging brands to offer fish gelatin or plant-based softgels. South Africa has a well-developed supplement retail sector and produces fish oil from local pelagic fisheries. Infant formula demand is rising across North and East Africa due to urbanization and higher birth rates.

• Rest of the World

The rest of the world holds a 4.8% share, mainly covering Latin American markets such as Brazil, Argentina, Chile, and Peru. Brazil represents 46.2% of this regional demand, supported by a growing supplement culture, large pharmacy networks, and rising cardiovascular health awareness. Peru and Chile play a vital role on the supply side, as their anchovy and jack mackerel fisheries produce a large portion of the crude fish oil used in global EPA/DHA refining. Local consumption, however, remains lower than in North America and Europe because of price sensitivity and limited awareness of daily intake recommendations. Sports nutrition, beauty-from-within products, and fortified dairy are creating new entry points for omega-3 brands. 

KEY INDUSTRY PLAYERS

The EPA/DHA omega-3 market is moderately fragmented, combining established supplement brands with fast-growing direct-to-consumer players. Leading companies such as WHC and Viva compete through high-concentration triglyceride formulas, independent purity certification, and strong online visibility. OmegaVia, Nutrigold, and Omax3 focus on premium positioning, transparent sourcing, and condition-specific products for heart, mood, and joint health. Emerging brands, including InnovixLabs, target vegan and value-conscious buyers with algal and triple-strength options. Competitive strategies include partnerships with ingredient refiners, sustainability certifications, subscription sales, and expansion into pharmacy and international e-commerce channels to strengthen market positioning.

List of Top EPA/DHA Omega-3 Companies

• WHC
• Viva
• OmegaVia
• WHC
• Nutrigold
• Omax3
• The
• Ocean
• InnovixLabs
• Controlled

LEADER INSIGHTS

• WHC Labs: Bart van Zwol, CEO and co-owner of WHC Labs, highlighted the relationship between rising business demand and the challenges of maintaining sufficient inventory. He noted that the company's expansion and increasing sales, particularly in China, make demand forecasting difficult, reinforcing the importance of inventory planning and supply-chain resilience for omega-3 supplement businesses. (Published: April 15, 2026 | Source: https://www.nutraingredients.com/)

• Viva Naturals: Candice Yin, who handles China e-commerce for Viva Naturals, discussed how cross-border e-commerce has enabled the company to expand its international business. Increasing demand from China supported the expansion of fish oil processing capacity in Canada and additional manufacturing activity, demonstrating how digital distribution and international consumer demand can create growth opportunities for omega-3 supplement brands. (Published: March 10, 2022 | Source: https://www.buzzsprout.com)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the EPA/DHA omega-3 market is focused on securing sustainable raw materials, expanding concentration capacity, and scaling algal production. Ingredient suppliers are funding fermentation facilities that reduce dependence on marine fisheries, while supplement brands invest in testing laboratories and traceability systems. Algal-derived EPA/DHA accounted for 14.2% of new product launches in 2025, attracting venture funding into microalgae strain development and downstream processing. Opportunities also exist in pharmaceutical-grade concentrates, clinical nutrition, and pet health. Emerging markets in Asia Pacific, which holds a 24.7% share, offer strong potential for brands willing to invest in local distribution and regulatory registration.

NEW PRODUCT DEVELOPMENT

New product development in the EPA/DHA omega-3 market centers on higher potency, better taste, and improved absorption. Manufacturers are launching re-esterified triglyceride concentrates, phospholipid-bound formulas, and self-emulsifying systems that enhance bioavailability when taken without meals. Concentrated oils above 60% purity now represent 47.3% of ingredient volume, enabling smaller capsules with higher EPA and DHA per serving. Brands are also introducing gummies, liquid shots, and flavored powders for children and pill-averse adults. Vegan softgels, specialized prenatal blends with choline, and condition-specific EPA formulas for mood and joint health are expanding portfolios and helping companies differentiate in crowded retail channels.

RECENT DEVELOPMENTS

• June 2026 – WHC announced the launch of its flagship UnoCardio 1000 omega-3 supplement in Singapore, strengthening its presence in Southeast Asia. The product emphasizes high-purity EPA/DHA concentrates, re-esterified triglyceride technology, and sustainable marine sourcing. This expansion supports growing regional demand for premium cardiovascular health supplements and independently tested omega-3 formulations.

• October 2026 – OmegaVia published updated educational resources covering triglyceride-form fish oil, omega-3 absorption, and cardiovascular health. The company continued promoting its high-concentration EPA/DHA portfolio, including EPA 500, DHA 600, and vegan omega-3 supplements. These activities reinforce its emphasis on formulation transparency, independent testing, and condition-specific nutritional products.

• June 2026 – InnovixLabs: InnovixLabs documented its active nutritional supplement portfolio, including Triple Strength Omega-3, with continued emphasis on science-based formulations and independent quality testing. Its product positioning supports demand for concentrated fish oil supplements designed for cardiovascular, cognitive, and general wellness applications. The available evidence confirms portfolio activity but not a new product launch.

REPORT COVERAGE

This report on the EPA/DHA omega-3 market provides a detailed assessment of market structure, segmentation, regional performance, competitive landscape, and recent strategic developments. It analyzes capsule EPA and powder EPA types along with 5 key applications, including nutritional supplements, which hold a 41.2% share. Regional analysis covers North America, Europe, Asia Pacific, Middle East & Africa, and the rest of the world. The report examines drivers, restraints, opportunities, and challenges, along with investment trends and product innovation. It supports manufacturers, ingredient suppliers, investors, and distributors in making informed decisions on sourcing, formulation, positioning, and expansion strategies.